Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma

Kim, Yuna; Lee, Yong Sang; Lee, Jae Seung; Jeon, Mi Young; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Um, Soon Ho; Seo, Yeon Seok; Kim, Seung Up

doi:10.1080/07357907.2020.1870126

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the median tumor size in our cohort was 2.9 cm, which was smaller than that in the cohort studied by Han et al, which ranged from 3.0 to 8.5 cm, depending on the subgroup. At our institute, intermediate stage or advanced HCC patients with vascular invasion, significant tumor burden of more than 10 cm, or infiltrative HCC were more likely to be treated with transarterial radioembolization [ 22 ] or liver-directed concurrent chemoradiotherapy [ 23 ]. Consequently, TACE has been frequently applied to patients with with nodular HCC presenting with relatively lower heavy tumor burden at our institute.…”

Section: Discussionmentioning

confidence: 99%

Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization

Kim

Lee

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

This study attempted to validate the prognostic performance of the proposed Pre- and Post-TACE (transarterial chemoembolization)-Predict models, in comparison with other models for prognostication. One-hundred-and-eighty-seven patients with HCC who underwent TACE were recruited. Regarding overall survival (OS), the predictive performance of the Pre-TACE-Predict model (one-year integrated area under the curve (iAUC) 0.685 (95% confidence interval (CI) 0.593–0.772)) was better than that of the Post-TACE-Predict model (iAUC 0.659 (95% CI 0.580–0.742)). However, there was no significant statistical difference between two models at any time point. For comparison between models using pre-treatment factors, the modified hepatoma arterial embolization prognostic (mHAP)-II model demonstrated significantly better predictive performance at one year (iAUC 0.767 (95% CI 0.683–0.847)) compared with Pre-TACE-Predict. For comparison between models using first TACE response, the SNACOR model was significantly more predictive at one year (iAUC 0.778 (95% CI 0.687–0.866) vs. 0.659 (95% CI 0.580–0.742), respectively) and three years (iAUC 0.707 (95% CI 0.646–0.770) vs. 0.624 (95% CI 0.564–0.688), respectively) than the Post-TACE-Predict model. mHAP-II and SNACOR may be preferred over the Pre- and Post-TACE-Predict models, respectively, considering their similar or better performance and the ease of application.

show abstract

Section: Discussionmentioning

confidence: 99%